Workflow

Reduce expensive uncertainty in breast imaging workflows

The workflow case for BreastScreening-AI is about turning diagnostic uncertainty into measurable operations: fewer avoidable callbacks, better triage of complex cases, safer follow-up, and a governance trail that can convert clinical performance into budget impact.

Cost of avoidable callbacksReader allocation strategySecond-reader pathway designDiagnostic safety economics

Business workflow thesis

Every false alarm consumes capacity, budget and patient confidence

Screening programmes create value by finding disease earlier, but false positives, overdiagnosis, missed findings and delayed follow-up create operational drag. The opportunity is not to replace clinical teams; it is to help them route attention, evidence and follow-up more efficiently.

USD 4B

Annual US false-positive and overdiagnosis spend

Health Affairs estimated national expenditure for false-positive mammograms and breast cancer overdiagnoses at about USD 4 billion per year.

Health Affairs source
17.5%

Diagnostic-error budget exposure

The OECD diagnostic-safety report estimates the direct consequences of diagnostic error at 17.5% of healthcare expenditure in a typical OECD country.

OECD source
Up to 15%

Diagnoses inaccurate, delayed or wrong

OECD summarizes diagnostic safety evidence indicating that up to 15% of diagnoses may be inaccurate, delayed or wrong depending on setting.

OECD source
USD 870B

US diagnostic-error cost frame

The OECD report translates diagnostic-error consequences to about USD 870 billion annually in the United States across healthcare budgets.

OECD source
USD 676B

OECD-wide savings if errors are halved

OECD estimates that halving diagnostic error could free as much as 8% of healthcare expenditure, equivalent to USD 676 billion yearly across OECD countries.

OECD source
2.2%

Recall rate in a randomized AI screening trial

The MASAI interim safety analysis reported similar recall rates in AI-supported and standard double-reading groups, supporting a workflow claim about maintaining operational safety while changing reading allocation.

Lancet Oncology source

Impact model

What reducing avoidable diagnostic waste could mean

The uploaded OECD report cites the Health Affairs estimate that false-positive mammograms and overdiagnosis cost about USD 4 billion yearly in the United States. The model below converts that burden into conservative reduction scenarios.

Scenario calculator

Annual gross value = USD 4B baseline x achievable reduction. This is a directional macro model, before software, integration, monitoring, training, regulatory, legal and change-management costs.

5% reduction
USD 200M
10% reduction
USD 400M
25% reduction
USD 1.0B
50% reduction
USD 2.0B
USD 4B

Targetable workflow waste

Not all of the USD 4B is addressable by AI. The addressable share depends on local recall patterns, case mix, reading protocol, reimbursement, and whether the system reduces callbacks without increasing missed cancers.

Evidence boundary: this model does not claim BreastScreening-AI currently realizes these savings. It shows why reducing false positives is economically material and what hospital pilots should measure to build a credible local business case.

Operating model

Design the workflow around economic control points

A hospital-grade workflow should show where value is created, where risk is controlled and where data are captured for future reimbursement, procurement and validation decisions.

01 Demand

Screening queue

Track volume, eligibility, breast density, priors and modality availability before clinical interpretation begins.

02 Triage

Risk routing

Use AI as a prioritization and second-reader signal, with high-risk or uncertain studies routed to deeper review.

03 Recall

Callback governance

Measure recalls, additional imaging and biopsy recommendations so false positives become a controllable metric.

04 Multimodal

MG, US and MRI

Escalate from screening mammography to targeted ultrasound or MRI when clinical questions require more evidence.

05 Safety

Missed-case review

Track disagreement, follow-up outcomes, interval cancers and failure-to-follow-up events over time.

06 Value

Budget impact

Translate workflow outcomes into gross savings, implementation cost, risk reduction and adoption evidence.

Multimodality

Why breast imaging needs one workflow logic

Multimodality is a cost-control problem as much as a clinical one: the goal is to use the right evidence at the right time, avoiding both missed disease and unnecessary escalation.

MG

Mammography

High-volume screening entry point where false positives, density, priors and recall decisions create the largest aggregate operational burden.

Business metric: callback and benign workup rate.
US

Ultrasound

Targeted characterization layer for suspicious or palpable findings, where workflow value comes from faster clarification and fewer avoidable escalations.

Business metric: workup completion and biopsy yield.
MRI

MRI

Complex-case and high-sensitivity layer where value depends on prioritizing the right patients and reducing review complexity across volumes and sequences.

Business metric: complex-case throughput and escalation appropriateness.

Governance and adoption

The value case must be measured, not assumed

BreastScreening-AI speak to decision-makers who care about clinical credibility, operational control and economic upside. The safest positioning is validation-first: prove local value before scale-up.

Economic KPIs

  • Recall rate and false-positive burden.
  • Additional imaging and benign biopsy volume.
  • Reader allocation and second-reader workload.
  • Gross cost avoided versus implementation cost.

Clinical safety KPIs

  • False negatives and interval cancers.
  • Detection of aggressive subtypes.
  • BI-RADS decision changes and disagreement.
  • Follow-up completion and escalation appropriateness.

Adoption KPIs

  • Reader trust and override behavior.
  • Training time and support requests.
  • Workflow fit by modality and seniority.
  • Audit completeness and governance readiness.

Commercially useful, clinically careful

BreastScreening-AI can be positioned as workflow infrastructure for reducing avoidable diagnostic waste and improving breast-imaging coordination. It should not be positioned as autonomous diagnosis, guaranteed savings, regulatory clearance, or medical advice.

Review evidence boundaries
Validation firstDeployment principle

Local pilots should estimate addressable false-positive spend, reader allocation, recall outcomes and total implementation cost before any scale-up decision.

Explore the platform behind the workflow

Review product capabilities, evidence boundaries and the broader platform strategy.

Explore platform Review evidence